The main direction of new crown drug research and developmentFrom the end of 2019, the new crown virus has been It has been raging on the earth for 3 years. The earliest mutant strain that caused a large epidemic in the world was the D614G strain, followed by Alpha, Beta, Gamma, and Delta strains. Omicron has taken over as the most prevalent strain today. The evolution characteristics of these new coronavirus epidemic strains are mainly in two points: 1, increase the transmission ability 2, reduce the neutralization ability of antibodies. The Delta strain (Delta) has the characteristics of short infection incubation period, strong pathogenicity, and rapid onset progression in addition to its strong transmission ability. It is more contagious, but causes milder symptoms, and the Omicron variant has not been found to cause an increase in severe disease and mortality. At the same time, existing research results show that the Omicron variant has not completely immune escape from existing vaccines . Because Omicron has the characteristics of strong transmission, strong concealment, and many asymptomatic infections, my country’s current policy to deal with the epidemic is to adhere to “dynamic clearing” and make good use of nucleic acid + antigen self-testing. Joint testing strategy to implement the “four early” (early detection, early reporting, early isolation and early treatment). In order to reduce the cost of the society and the burden of medical resources, the main directions of the research and development of domestic new crown treatment drugs that are highly expected are: 1. For the treatment of asymptomatic and mild to moderate infections, less Contraindications to expand the scope of the user population, quickly shorten the negative conversion time, reduce the conversion to severe disease and the fatality rate; 2. For the treatment of severe cases, it is more effective to promote the improvement of the condition and reduce the fatality rate; 3. For the prevention of post-exposure populations, play a role in The effect of prevention without being infected. treatmentClinical application and research and development progress of new crown drugs< /span>According toMarch 14, 2022 Domestic< /span>The latest “New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Ninth Edition)”, Antiviral treatment drugs include anti-small molecule drugs ( Pfizer’s Paxlovid), neutralizing monoclonal antibody (Tengsheng‘s Ambavirumab/Romisevirumab Injection), intravenous injection of COVID-19 Immune globulin, convalescent plasma of recovered patients. Other drug treatments are divided into immunotherapy (glucocorticoids and interleukin-6), anticoagulation therapy (heparin), and traditional Chinese medicine (multiple prescriptions and several proprietary Chinese medicines). ComparisonApril 21, 2022< /strong>World Health Organization (WHO) updated COVID-19 treatment guidelines in the British Medical Journal: For mild cases , the important recommended treatment drug is Pfizer’s Paxlovid, and the conditional recommendation is Merck’s Molnupiravir, Remdesivir（Remdesivir） , and monoclonal antibodies Sotrovimab and REGN-COV2; for severe cases, cortisol hormones, IL-6 inhibitors and JAK inhibitor Baricitinib are strongly recommended. Domestic companies are in the process of developing drugs to treat COVID-19, neutralizing antibodies including ambavirumab/romi Both selvizumab and eltemirumab are approved. Among the more anticipated small-molecule chemical drugs, the ones with faster progress are Prolukamide from Kintor, VV16 from Junshi Bio, and Azvudine from Real Bio. Among them, the data of Kintor and Real Bio will be fully disclosed in the near future, and Junshi Bio’s VVI6 is conducting head-to-head clinical trials with Pfizer Paxlovid for the treatment of mild to moderate diseases. Pfizer’s Paxlovid has the best clinical data on small molecule treatments for COVID-19: compared to placebo, it reduces the risk of COVID-19-related hospitalization or death by 89% (within 3 days of onset of symptoms). However, Pfizer’s latest disclosure of Paxlovid’s post-exposure prophylaxis trial failed, and the data was not statistically significant. 
Source: New crown drugs developed by domestic enterprises (fast progress), organized by Zhongkang Industrial Research Center span>New crown treatment drugs may respond to the trendCurrently, the mutation characteristics of the new crown virus are developing in the direction of increasing transmission , the most obvious urgent need for new drugs is to rapidly shorten the time of negative conversion and enhance the ability of post-exposure prevention, reducing the burden of medical and social resources and the infection of more people. In the future, if the new crown mutation develops in the direction of greater pathogenic ability and reduced antibody neutralization ability, this requires betterbetterbroad-spectrum New crown treatment drugs to deal with virus mutation.
